The Vyvgart (Efgartigimod) market size was valued at USD 2.23 billion in 2024 and is expected to reach USD 6.21 billion by 2032, growing at a CAGR of 13.67% over 2025-2032.
The Vyvgart (Efgartigimod) market is expected to grow very rapidly. Especially the increase in the autoimmune disease incidence, the increase in FDA and EMA approved number, and the increasing importance of biopharma company investments to reduce the autoimmune pain take the North America region’s market to the top. Efgartigimod, a neonatal Fc receptor (FcRn) inhibitor that is first-in-class, has made forays into the treatment of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), and has received regulatory nods in the U.S., China, EU, and Japan. The Vyvgart (Efgartigimod) market can also benefit from further clinical data, such as from phase 3 trials (e.g., ADAPT and ADHERE), which demonstrate significant improvements in symptoms and functional scores. The U.S. Vyvgart (Efgartigimod) market is heavily buoyed by the approval of the self-injectable Vyvgart Hytrulo (Apr 2024), improving patient convenience and compliance.
In April 2025, the FDA approved Vyvgart Hytrulo in a pre-filled syringe, making it easier for patients to administer and lessening the dosing burden.
Factors that are driving the Vyvgart (Efgartigimod) market growth include the growing R&D expenditure– Argenx alone, which spent more than USD 600 million on R&D in 2023, directly dedicated towards CIDP, ITP, and additional IgG-mediated diseases. In addition, continued partnerships such as Argenx and Zai Lab (China) and EU positive CHMP opinions have increased international access. Supply chains are growing along with demand. Argenx has also extended its active development programs into the United States, Japan, China, and South Korea, providing a larger pan-regional presence in key markets around the world. Prescriptions and provider adoption every month have grown in real-world use across neurology and immunology.
Regulatory FDA's drug trials snapshot (2024) confirms drug effectiveness and safety across multiple demographics. Moreover, peer-reviewed publications of real-world data confirm GR in real life. The market share for Vyvgart (efgartigimod) is expected to increase as good reimbursement and a trend towards physician preference of targeted therapies over traditional immunosuppressants will help drive growth. The companies behind Vyvgart (Efgartigimod), Argenx with its leaches and followers, are also exploring new concepts such as making child-friendly versions and combining treatments, a fact that contributes to maintaining an optimistic market analysis and future planning for Vyvgart (Efgartigimod).
In May 2024, Argenx and Zai Lab announced regulatory approval for Vyvgart in CIDP in China, a key milestone in the internationalization of the Vyvgart (Efgartigimod) market.
Drivers:
Rising Clinical Applications, R&D Investments, and Expedited Approvals Fuel Demand
A key driver of the market includes the increasing incidence of antibody-mediated autoimmune diseases and a surge in the number of indications undergoing clinical trials. Growing interest in blocking the FcRn selectively is driven by compelling clinical data in diseases such as ITP, PV, and MMN. Argenx is actively running several Phase II/III studies and has more than 12 indications in the pipeline as of 2024. This broadening has fueled a demand increase in the global Vyvgart (efgartigimod) market within neurology and immunology. R&D investments are also on the rise, and Argenx estimates investing €807 million (~USD 875 million) in R&D by 2023, demonstrating the industry’s enthusiasm for FcRn modulation.
Moreover, the FDA’s orphan drug designation for efgartigimod in several indications and the breakthrough therapy designation for CIDP have shortened the development timeline and expanded market opportunities. Clinical practice guidelines and expanding payer coverage of individualized immunotherapy also drive adoption. Biopharma companies are also undertaking numerous collaborations (e.g., argenx–Horizon Therapeutics and argenx–Stichting Sanquin), suggesting a strong expanding ecosystem. Alongside those factors, increased production capabilities and improved methods of access (subcutaneous, as well as I.V.) are helping to accelerate the rate at which doctors are using, and patients can get, Vyvgart (Efgartigimod).
Restraints:
High Therapy Costs, Competitive Landscape, and Access Gaps Create Barriers
Even with robust Vyvgart (efgartigimod) market trends, high treatment costs and restricted reimbursement are significant headwinds. The mean annual cost of Vyvgart treatment per patient may exceed USD 400,000 in the U.S., which represents a substantial access point, particularly for underinsured patients. Although subcutaneous formulations reduce the inconvenience, they do not bring the latter with the overall costs.
The rise of rival FcRn-targeted drugs like Johnson & Johnson’s nipocalimab and UCB’s rozanolixizumab could dilute Vyvgart (Efgartigimod) market potential. These peers are winning regulatory victories and demonstrating similar efficacy profiles, adding to pricing, formulary pressure. Also, differences in drug approval and labelling between nations (e) e.g., slower uptake in jurisdictions where inflexible pharmacoeconomic assessments are the norm, like Canada or some EU countries) made for non-uniformity of access. High cost and lack of widespread distribution in LMICs are also barriers to worldwide access. The delayed diagnosis and underdiagnosis of gMG and CIDP in emerging regions also delay patients’ medication-seeking behavior and therefore the realized potential of market expansion, despite the unmet demand and merit of gMG and CIDP. These structural and financial obstacles are also obstructing equitable growth in the global Vyvgart (Efgartigimod) market.
By Indication
The Generalized Myasthenia Gravis (gMG) was the leading segment in 2024 on the basis of revenue and had the largest market revenue share of 97.68% in the Vyvgart (Efgartigimod) market. This position may be primarily explained by early gMG FDA approval (in 2021), robust real-world clinical data, and broad prescriber familiarity. The large and diverse patient population, combined with improved awareness and diagnosis, means that Vyvgart has been widely accepted as the first-in-class FcRn blocker in gMG. In addition, clinical guideline recommendations and increasing payer acceptance have driven up utilization rates.
In contrast, CIDP is forecasted to be the fastest-growing market segment, due to the FDA’s 2024 approval for this indication and positive outcomes from the Phase 3 ADHERE study. The clearance has made a large patient population seeking other treatments besides steroids and IVIg available for access. Argenx’s build-out of its CIDP-oriented R&D and expansion into new markets such as China (via Zai Lab) should help fuel this segment’s growth trajectory in a big way.
By Route of Administration
By route of administration, the market was led by the Intravenous (IV) Infusion segment of Vyvgart (efgartigimod) in 2024 with 95.78% share. That leadership comes courtesy of its earlier regulatory green light and broad usage in the clinical practice environment, including but not limited to hospitals and infusion centers. Since Vyvgart first entered the market, the IV preparation’s long-standing safety profile and low dose familiarity have established it as a reasonable default option.
The prefilled syringe segment is expected to grow at the fastest pace during the forecast period. The introduction of Vyvgart Hytrulo self-administered prefilled syringe (April 2025 FDA approval) has brought great convenience to the patients, lessening the need for repeated visits to the clinic. This dosing approach can be self-administered at home, which increases compliance and access for the patient, especially in chronic conditions that need consistent long-term treatment. Increased productivity, coupled with rapid adoption among neurologists and immunologists, is anticipated to drive the market share.
North America was the most prominent regional Vyvgart (Efgartigimod) market in 2024, which contributed to 88.2% market share, on account of early approvals from the FDA, robust healthcare infrastructure, and broad reimbursement coverage. The USW is a stronghold, with Vyvgart uptake accelerated for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The U.S. Vyvgart (Efgartigimod) market size was valued at USD 1.51 billion in 2024 and is expected to reach USD 3.82 billion by 2032, growing at a CAGR of 12.38% over 2025-2032. Wide-reaching commercial availability, patient assistance programs, and high rates of diagnosis have further supported US dominance. In Canada, uptake has started, but market access is still small because of more restrictive health technology assessments and slower approvals than in the U.S. Mexico is a slow-growing market driven by expanding health care for rare diseases and demand for innovative immunotherapies.
Vyvgart (Efgartigimod) market in Europe is the second fastest growing, supported by the growing burden of autoimmune diseases and regulatory developments – CHMP’s positive opinion for CIDP. Germany stands at the forefront of the region due to its sophisticated reimbursement system, high level of clinical trial enrollment, and represents the largest market in Europe for Vyvgart. Phenomenal backing of rare disease societies and progressive incorporation of treatment protocols in France and the UK are driving penetration in the market. Italy and Spain are doing the same, with higher coverage as a result of in-hospital formulation administration and recent inclusion in the payer reimbursement catalogue. Turkey and Poland have sizeable patient pools with growth potential but are plagued by regulatory sluggishness.
Among other regions, Asia Pacific is the fastest-growing Vyvgart (Efgartigimod) market, with increasing regulatory approvals and partnerships. China leads the charge, and approval of Vyvgart Hytrulo (2024) for CIDP is a significant step on the road to market, with Argenx and Zai Lab teaming up. Japan, which was already a solid gMG market for Vyvgart given its prior gMG approval, remains a high clinical adopter driven by aging and a higher incidence of autoimmune disease. India and South Korea are seeing rising demand, higher awareness, diagnosis rates, and ongoing efforts to simplify regulatory pathways. Early access. Under early access schemes and strong local clinical trial ecosystems, Singapore and Australia are using the superior SPV technology that promises greater access, enabling more people to take up vaccines.
Argenx SE, Zai Lab Limited, Halozyme Therapeutics Inc., Pfizer Inc., UCB Pharma, Johnson & Johnson (Janssen), Alexion Pharmaceuticals (AstraZeneca), Horizon Therapeutics, Immunovant Inc., and Takeda Pharmaceutical Company Limited.
In April 2025, Argenx announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the approval of VYVGART (efgartigimod alfa) for subcutaneous monotherapy in adult patients with progressive or relapsing active CIDP, particularly those previously treated with corticosteroids or immunoglobulin therapies.
In April 2025, argenx SE secured FDA approval for a prefilled syringe formulation of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), allowing self-administration by adult patients with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive, as well as those with chronic inflammatory demyelinating polyneuropathy (CIDP).
In Nov 2024, China’s NMPA approved Vyvgart Hytrulo as the first-ever CIDP therapy in the country, marking a pivotal milestone. The once‑weekly subcutaneous treatment strengthens the argenx–Zai Lab alliance and broadens treatment options for patients with limited access to alternatives such as IVIg.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 2.23 billion |
| Market Size by 2032 | USD 6.21 billion |
| CAGR | CAGR of 13.67% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Indication (Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Generalized Myasthenia Gravis (gMG), and Others) • By Route of Administration (Intravenous (IV) Infusion, Subcutaneous (SC) Injection, and Prefilled Syringe) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Argenx SE, Zai Lab Limited, Halozyme Therapeutics Inc., Pfizer Inc., UCB Pharma, Johnson & Johnson (Janssen), Alexion Pharmaceuticals (AstraZeneca), Horizon Therapeutics, Immunovant Inc., and Takeda Pharmaceutical Company Limited. |
Ans: The Vyvgart (Efgartigimod) Market is projected to grow at a CAGR of 13.67% during the forecast period.
Ans: By 2032, the Vyvgart (Efgartigimod) Market is expected to reach USD 6.21 billion, up from USD 2.23 billion in 2024.
Ans: A key driver of the market includes the increasing incidence of antibody-mediated autoimmune diseases and a surge in the number of indications undergoing clinical trials.
Ans: Even with robust Vyvgart (efgartigimod) market trends, high treatment costs and restricted reimbursement are significant headwinds.
Ans: North America is the dominant region in the Vyvgart (Efgartigimod) market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Indicated Conditions (2024)
5.2 Prescription and Utilization Trends (2024), by Region
5.3 Healthcare Spending and Reimbursement Trends (2024), by Region
5.4 Regulatory and Market Expansion Insights
5.5 Patient Demographics and Stratification Trends (2024)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Vyvgart (Efgartigimod) Market Segmentation By Indication
7.1 Chapter Overview
7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trend Analysis (2021-2032)
7.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Generalized Myasthenia Gravis (gMG)
7.3.1 Generalized Myasthenia Gravis (gMG) Market Trends Analysis (2021-2032)
7.3.2 Generalized Myasthenia Gravis (gMG) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Others
7.4.1 Others Market Trends Analysis (2021-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Vyvgart (Efgartigimod) Market Segmentation By Route of Administration
8.1 Chapter Overview
8.2 Intravenous (IV) Infusion
8.2.1 Intravenous (IV) Infusion Market Trends Analysis (2021-2032)
8.2.2 Intravenous (IV) Infusion Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Subcutaneous (SC) Injection
8.3.1 Subcutaneous (SC) Injection Market Trends Analysis (2021-2032)
8.3.2 Subcutaneous (SC) Injection Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Prefilled Syringe
8.4.1 Prefilled Syringe Market Trends Analysis (2021-2032)
8.4.2 Prefilled Syringe Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.2.4 North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.2.5.2 USA Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.2.6.2 Canada Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.2.7.2 Mexico Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.4 Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.5.2 Germany Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.6.2 France Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.7.2 UK Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.8.2 Italy Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.9.2 Spain Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.10.2 Poland Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.11.2 Turkey Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.4 Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.5.2 China Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.5.2 India Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.5.2 Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.6.2 South Korea Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.7.2 Singapore Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
8.4.8.2 Australia Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.5.2 UAE Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.7.2 Qatar Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.8.2 South Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.6.4 Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.6.5.2 Brazil Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.6.6.2 Argentina Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10. Company Profiles
10.1 Argenx SE
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 Zai Lab Limited
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Halozyme Therapeutics Inc.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Pfizer Inc.
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 UCB Pharma
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Johnson & Johnson (Janssen)
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 Alexion Pharmaceuticals (AstraZeneca)
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Horizon Therapeutics
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 Immunovant Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 Takeda Pharmaceutical Company Limited
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Generalized Myasthenia Gravis (gMG)
Others
By Route of Administration
Intravenous (IV) Infusion
Subcutaneous (SC) Injection
Prefilled Syringe
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players